What is KNSA's P/E ratio?

KINIKSA PHARMACEUTICALS LTD (KNSA) currently trades at a P/E ratio of 75.65.

KINIKSA PHARMACEUTICALS LTD reports a Return on Equity (ROE) of 12.33%.

What is KNSA's dividend yield?

KINIKSA PHARMACEUTICALS LTD offers a dividend yield of 0.00%.

What is KNSA's Quality Score?

Our AI rates KNSA's overall financial quality at 62 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy KNSA?

Our AI Timing Score for KNSA is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does KNSA belong to?

KINIKSA PHARMACEUTICALS LTD is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange

KNSA (NASDAQ) Stock Analysis | KINIKSA PHARMACEUTICALS LTD

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-06-30)

KNSA AI Analysis Summary

Our AI summary for KNSA: KINIKSA PHARMACEUTICALS LTD (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 75.65, ROE of 12.33%, a dividend yield of 0.00%. Its financial Quality Score stands at 62/100 — mid-range fundamentals relative to the market. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

KNSA

KINIKSA PHARMACEUTICALS LTD

US:NASDAQ STOCK Healthcare >> Drug Manufacturers - Specialty & Generic

USD 74.34

-3.86 (-4.94%) Day Change

Watchlist Portfolio Compare Chart

75.65

P/E

0.01

D/E

12.3%

ROE

9.0%

ROA

0.00%

Div Yield

-0.31

PEG

KINIKSA PHARMACEUTICALS LTD
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 74.34 Price -3.86 (-4.94%) Day Change	NEWS SCORE: N/A

KNSA, the overall quality is ok ( Quality = 62) and the timing to buy is ...(Sign In to See)...

Loading chart...

62 QUALITY

Signal: NEUTRAL

Signal Description: Company financial health is OK

Reason: P/E ratio is relatively high
ROE is relatively low.
Acceleration of ROE growth rate is below our criteria.
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...

Quality Factors

47%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	N/A
Magic Formula Rank by ROA	2147
Magic Formula Rank by ROE	2147
Magic Formula Rank by ROIC	1721
Price	74.34
PBV / Sector	9.33 / 3.22
Earning Per Share	0.98

PE / Sector	75.65 / 29.79
PEG or PE/Growth / Sector	-0.31 / 0.13
Average 1M Daily Value	54.61 M
Average 1W Daily Value	107.80 M GREAT

Timing Factors

71%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

50%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

56%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	9.59 / 15.21
NPM Average (%) / Sector	19.32 / -10.83 GREAT
NPM Change Average (%) / Sector	-141.19 / 117.42
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	9.00 / 8.15
ROA Average (%) / Sector	10.37 / 2.87
ROA Change Average (%) / Sector	-164.67 / 112.70
ROE (%) / Sector	12.33 / -1.02
ROE Average (%) / Sector	12.47 / 8.35
ROE Change Average (%) / Sector	-171.73 / 385.91
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.51
Dividend Average (%) / Sector	N/A / 3.06
Dividend Change Average (%) / Sector	N/A / 13.64

Registration Details

Analyze Date	2026-08-01 08:00:05
Symbol	KNSA
Name	KINIKSA PHARMACEUTICALS LTD
Sector	Healthcare >> Drug Manufacturers - Specialty & Generic
Market	NASDAQ
Listed Shares	48.29 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	6,101.48 / 10,754.62

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 105 Piccadilly, London, United Kingdom, W1J 7NJ

Phone: 44 78 1431 9100

Website: https://www.kiniksa.com

Employees: 366

Sector: Healthcare >> Drug Manufacturers - Specialty & Generic

Description: Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.